Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment.
INTRODUCTION Long-acting injectable (LAI) antipsychotics improve schizophrenia treatment adherence compared with oral antipsychotics but remain underused. TV-44749 is an innovative, once-monthly, subcutaneous (SC) LAI olanzapine designed to provide sustained efficacy through controlled olanzapine release over the month...